2026 08 26 Autoresearch Biosecure Wuxi 1260h Injunction
DLA Piper 2026-08-24: DC court PI on 2026-08-07 bars DoD from enforcing WuXi AppTec's June 8 1260H listing. OMB BCOC list still due 2026-12-18. Still no 2026 realized mAb fill-finish price series. Human call on TMO chain continues — ninth day.
Summary
New dated legal fact, not a realized-price print. DLA Piper (24 Aug 2026): WuXi AppTec was added to DoD's Section 1260H list on June 8, 2026; it sued June 11; on August 7, 2026 the US District Court for the District of Columbia issued a preliminary injunction barring DoD from enforcing or giving effect to that designation while the case proceeds. The court's ownership finding: AVIC's stake was 0.001% of WuXi AppTec ($200k of open-market shares), not 5.32% of the company. That delays the compressed 60-day FAR clock that would have applied if WuXi were still an enforceable 1260H name when the FAR is revised.
The OMB initial BCOC list is still due December 18, 2026 — that independent pathway is untouched. Medicare Part B/D are out of FAR "contract" scope on DLA Piper's plain reading.
Still no independent 2026 realized mAb fill-finish / CDMO price series that would reconcile Mordor's −15% 2023–2025 history with the asserted Western pricing-power step. Consultant 5–10% / 15–30% figures remain forecasts. Do not silently downgrade biosecure-cdmo-scarcity-to-western-cdmo-pricing-power. Human call, now with an injunction that pushes the 1260H-accelerated path out without killing the OMB list.
China's June 22 MOFCOM list includes MP Materials (export-control, military-use products) — adjacent, not a CDMO fact; do not mix into TMO.
Findings
- Injunction (primary legal recap). 1260H expansion June 8 included WuXi AppTec (188 entities). PI Aug 7: DoD cannot enforce the designation. Ownership theory collapsed: 5.32% was WuXi-in-AVIC-fund, not AVIC-in-WuXi.
- Two BCC pathways remain. (a) 1260H + biotech involvement → 60-day post-FAR; currently enjoined for WuXi AppTec. (b) Independent OMB designation → 90-day post-FAR + five-year grandfather for pre-existing contracts. OMB list deadline 2026-12-18 unchanged.
- Absent the injunction, DLA Piper says a 1260H-path BCC designation for WuXi could have landed ~early 2028 (180-day guidance + 1-year FAR + 60 days). With the PI, that accelerated path is stayed; the five-year grandfather is the likelier default if OMB lists WuXi later.
- Medicare out of scope on a plain reading (FAR contract / 10 USC 4021 OT). Ultimate reach depends on OMB guidance.
- Pricing-power step still unmeasured in 2026. ResearchIntelo's 15–30% "BIOSECURE-compliant premium" is a market-research forecast, same class as Vision Life Sciences 5–10% — not a realized series. The hanging contradiction vs Mordor −15% (2023–2025) is not resolved.
Sources fetched
- https://www.dlapiper.com/en/insights/publications/2026/08/us-china-life-sciences-policy-developments-top-points-for-companies (Reliable-class law-firm alert; 24 Aug 2026)
- https://visionlifesciences.com/insights/biosecure-act-pharma-impact-2026 (consultant; forecasts only)
What this does not change
Step 3 of biosecure-cdmo-scarcity-to-western-cdmo-pricing-power stays partial. Conviction/status not moved unilaterally. TMO remains the named US-listed expression. OMB 2026-12-18 is still the dated list catalyst.